These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 12356647)

  • 1. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).
    Braunwald E; Antman EM; Beasley JW; Califf RM; Cheitlin MD; Hochman JS; Jones RH; Kereiakes D; Kupersmith J; Levin TN; Pepine CJ; Schaeffer JW; Smith EE; Steward DE; Theroux P; Gibbons RJ; Alpert JS; Faxon DP; Fuster V; Gregoratos G; Hiratzka LF; Jacobs AK; Smith SC;
    Circulation; 2002 Oct; 106(14):1893-900. PubMed ID: 12356647
    [No Abstract]   [Full Text] [Related]  

  • 2. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
    Araujo R; Agustí A
    Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849
    [No Abstract]   [Full Text] [Related]  

  • 6. [New thrombocyte aggregation inhibitor in therapy of unstable angina].
    Hamm C
    Z Kardiol; 2000 Nov; 89(11):1053-6. PubMed ID: 11149273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
    Gibson CM; Moynihan JL; Al-Mousa EN; Campsey M; Gandhi R; Murphy S; Mattson S; Ryan KA; Mesley R; Swanson J; Arshad MN; Marble SJ
    J Thromb Thrombolysis; 1999 Jun; 7(3):287-302. PubMed ID: 10375390
    [No Abstract]   [Full Text] [Related]  

  • 8. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
    Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention.
    Herrmann HC; Swierkosz TA; Kapoor S; Tardiff DC; DiBattiste PM; Hirshfeld JW; Klugherz BD; Kolansky DM; Magness K; Valettas N; Wilensky RL
    Am J Cardiol; 2002 Jun; 89(11):1293-7. PubMed ID: 12031731
    [No Abstract]   [Full Text] [Related]  

  • 10. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).
    Braunwald E; Antman EM; Beasley JW; Califf RM; Cheitlin MD; Hochman JS; Jones RH; Kereiakes D; Kupersmith J; Levin TN; Pepine CJ; Schaeffer JW; Smith EE; Steward DE; Theroux P; Gibbons RJ; Alpert JS; Faxon DP; Fuster V; Gregoratos G; Hiratzka LF; Jacobs AK; Smith SC; ;
    J Am Coll Cardiol; 2002 Oct; 40(7):1366-74. PubMed ID: 12383588
    [No Abstract]   [Full Text] [Related]  

  • 11. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
    Tcheng JE
    Am Heart J; 1999 Oct; 138(4 Pt 2):261-2. PubMed ID: 10502231
    [No Abstract]   [Full Text] [Related]  

  • 13. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK; Willerson JT
    Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract]   [Full Text] [Related]  

  • 14. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
    Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early use of glycoprotein IIb/IIIa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes.
    Marsh JD
    Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S15-26. PubMed ID: 12434711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction to "Optimizing management of non-ST-segment elevation acute coronary syndromes". Harmonizing advances in mechanical and pharmacologic intervention.
    Boden WE; Pepine CJ
    J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):1S-6S. PubMed ID: 12644334
    [No Abstract]   [Full Text] [Related]  

  • 18. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria.
    Kini AS; Reich D; Mitre CA; Sharma SK
    Am J Cardiol; 2001 Dec; 88(11):1287-90. PubMed ID: 11728356
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.